Clinical Study
Efficacy and Mechanism of Preoperative Simvastatin Therapy on Myocardial Protection after Extracorporeal Circulation
Table 1
Baseline characteristics and comorbidities.
| | Simvastatin () | Control () | value |
| Gender (male/female) | 20/36 | 22/32 | | Age (year) | | | 0.131 | Weight (kg) | | | 0.245 | Height (cm) | | | 0.094 | CPB duration (min) | | | 0.464 | Aorta clamping duration (min) | | | 0.296 | Atrial fibrillation (persons) | 14 | 12 | 0.847 | Diabetes (persons) | 2 | 3 | 0.742 | Ejection fraction EF (%) | | | 0.958 | Cardiac function (NYHA class) | | | 0.704 | I | 3 | 4 | | II | 14 | 15 | | III | 38 | 33 | | IV | 1 | 2 | | Blood lipid level | | | | Total cholesterol (mmol/L) | | | 0.171 | Triglyceride (mmol/L) | | | 0.056 | Low density lipoprotein (mmol/L) | | | 0.187 | High density lipoprotein (mmol/L) | | | 0.469 |
|
|
Data expressed as mean ± standard deviation. CPB: cardiopulmonary bypass; NYHA: New York Heart Association.
|